Dear CL:
Thanks for your respomse.
Now, what does "perform" mean?
Below is a recent recommendation.
Now I'll go look for a PCQuote?NewsAlert-Story of Nov. 26, 1996 that headlines:CytoTherapeutics and Genentech Collaborate on Development of Growth Fact-Based Therapeutics for CNS Diseases. It contains news of further funding for research.
Agreements cover Novel Delivery of Growth Factors to Treat Parkinson's and Huntington's Diseases and Amyotrophic Lateral Sclerosis.
RYE, N.H.--(BUSINESS WIRE)--Jan. 16, 1997--NeuroInvestment today announced its 1997
Recommended List, as was previously released to subscribers in the January issue. These are the
neuropharmaceutical companies that will outperform the market over the next 12 months. The
average gain for NeuroInvestment's Recommendations from 7/1/95-12/31/96 was 112%:
1) Interneuron (IPIC: recommended @ $10.31); Redux sales will grow, and we expect successful
completions of Phase III trials for both citicoline and bucindolol over the next six months, both of
which are going to be major drugs for large-scale needs.
2) Guilford (GLFD: recommended @ $10.57); The target is 35 due to Gliadel's launch for brain
cancer, plus promising programs in neuroimmunophilins and neuroprotection.
3) Neurex (NXCO: recommended @ $2.00); Approval for Corlopam and the year-end
completion of SNX-111's trials will bring Neurex to at least our price target of 28.
4) Gliatech (GLIA: recommended @ $8.25); Gliatech's growing European revenues for their
surgical adhesion products and US filings for FDA approval will bring the stock to 20.
5) Cambridge Neuroscience (CNSI: recommeded @ $9.50) will complete its Phase III trial for
Cerestat in head trauma this year; positive data will bring the stock to at least 25.
6) Cephalon (CEPH: recommended @ $25.75) benefits from the failure of Amgen/Regeneron's
competing drug for ALS. The FDA will approve Myotrophin expeditiously, through Provigil for
narcolepsy may not be reviewed this year. The cost of buying out its Myotrophin partners limits the
target to 50.
7) Cypros (CYPR: recommended @ $5.38) will continue to unveil data from a series of Phase II
studies, and will launch two or three Phase III trials for its promising lead compounds. The price
target is 10.
Added to the list are:
8) Cortex (CORX) returns to the List having resolved the financial
crisis which was so worrisome this past summer. With clinical data
for its novel lead compound coming mid-year in both Alzheimer's (for
which it has a unique mode of action addressing the basic process of
memory formation) and schizophrenia, the price target is 11.
9) Neurobiological Technologies (NTII) suffered a setback in its rheumatoid arthritis program,
which means that it is now very cheap, considering its pipeline of drugs in development for pain,
AIDS-dementia, and edema. Our price target is 6.
Other companies who are strong candidates for the List include
Cyto Therapeutics (CTII), CoCensys (COCN), and Diacrin (DCRN).
"The neuroscience sector had a lackluster year in 1996, as did biotech in general," said Dr. Harry
Tracy, publisher of NeuroInvestment. "However, many of these companies have made striking
progress towards offering effective, commercializable products. 1997 is going to see dramatic
developments in the generation of new treatments for such major disorders as stroke, head trauma,
and Alzheimer's. The recent failure of Regeneron's drug for ALS is a reminder of how difficult it is to
deliver growth factors effectively, but says nothing about the prospects for the sector as a whole.
"Biotech is in the first stage of what ultimately is going to
be a 10 to 15 year cycle of drug development which will revolutionize
medicine. Since many of the most destructive and hitherto
untreatable diseases are neurological disorders, the neuroscience
sector is going to be at the forefront of this transformation. 1997
should be a solid year with 50-100 percent gains for the best
companies in the sector. We expect that 1998 will be even better,
and the hierarchy of companies considered 'first-tier' will be both
much larger and quite different than it is today."
A one-year subscription to NeuroInvestment is $295, a two-year subscription is $550. A 3-month
trial subscription is $90. NeuroInvestment can be reached at P.O. Box 458, Rye, NH 03870.
Phone: 603-964-9640; Fax: 603-964-7561; E-Mail: neuroinv@nh.ultranet.com .
Founded in 1995, NeuroInvestment provides the most complete
independent analyst reports available to the public regarding
emerging companies specializing in the treatment of neurological
disorders. Neuroscience Stock Reports Inc. of Rye, N.H. is a
leading publisher of research information regarding neuroscience
companies.
CONTACT: NeuroInvestment
Dr. Harry M. Tracy, 603/964-9640
603/964-7561 (f) |
